<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01001260</url>
  </required_header>
  <id_info>
    <org_study_id>804975</org_study_id>
    <secondary_id>American Heart Association</secondary_id>
    <nct_id>NCT01001260</nct_id>
  </id_info>
  <brief_title>PGD2 Formation in Vascular Injury</brief_title>
  <acronym>PGD2</acronym>
  <official_title>Biosynthesis of PGD2 in Vascular Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the biosynthesis of PGD2 during percutaneous transluminal coronary angioplasty&#xD;
      (PTCA) procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A) To determine whether biosynthesis of PGD2 is altered in response to vascular injury in&#xD;
      humans&#xD;
&#xD;
      B) Patients will be grouped base on their aspirin using status. Three groups of no aspirin&#xD;
      but an alternative anti-platelet medicine, low dose (81 mg) aspirin, high dose 325 mg aspirin&#xD;
      will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to find subjects that met inclusion/exclusion criteria.&#xD;
  </why_stopped>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The increment of PGD2 synthesis reflected by an novel biomarker of urinary PGD2 metabolite.</measure>
    <time_frame>18-48 hours - which includes 24 hours before the procedure through 18 hours after the procedure for a continuous urine collection.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whether aspirin could blunt the increment of PGD2 if there is.</measure>
    <time_frame>18-48 hours - which includes 24 hours before the procedure through 18 hours after the procedure for a continuous urine collection.</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">51</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Stable Angina</condition>
  <arm_group>
    <arm_group_label>No Aspirin Treatment</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>81 mg Aspirin Treatment</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>325 mg Aspirin</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No ASA</intervention_name>
    <description>Alternative antiplatelet therapy instead of aspirin</description>
    <arm_group_label>No Aspirin Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose ASA</intervention_name>
    <description>Low dose aspirin (81mg) prior to PTCA</description>
    <arm_group_label>81 mg Aspirin Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>325 mg ASA</intervention_name>
    <description>high dose of aspirin prior to PTCA</description>
    <arm_group_label>325 mg Aspirin</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Specimens:&#xD;
&#xD;
           3 urine collections will be obtained (Prior to PTCA, During PTCA and Post PTCA)&#xD;
&#xD;
        -  Genetic Testing:&#xD;
&#xD;
      analysis of the association of SNPs in Cox genes with variability in selectively or in the&#xD;
      PGEs genes in quantitative biosynthesis of PGD2 and related compounds.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled to have PTCA&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with existing CAD admitted for elective PTCA:&#xD;
&#xD;
               1. Treated with any dose of aspirin daily for at least 5 days, with special interest&#xD;
                  in those treated with 81 mg aspirin daily or&#xD;
&#xD;
               2. Treated with an alternative antiplatelet therapy, such as clopidogrel, due to&#xD;
                  aspirin hypersensitivity or PMDs preference or&#xD;
&#xD;
               3. No aspirin therapy at all&#xD;
&#xD;
          -  Patients presenting to the ER with Acute Coronary Syndrome(ACS)who will have a PTCA&#xD;
&#xD;
          -  Patients with stable angina or positive stress tests scheduled for a cardiac&#xD;
             catheterization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of unstable diabetes (hgb A1c&gt;8 or FBS&gt; 200)&#xD;
&#xD;
          -  Uncontrolled hypertension (SBP &gt; 180, DBP &gt;100)&#xD;
&#xD;
          -  History of an acute confounding disease as judged on clinical screen that according to&#xD;
             the investigator may interfere with interpretation of the study results, or compromise&#xD;
             the safety of a potential subject.&#xD;
&#xD;
          -  Patients who have taken NSAIDS or COX-2 inhibitors other than aspirin, for at least 10&#xD;
             days prior to PTCA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Garret FitzGerald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wenliang Song, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 14, 2009</study_first_submitted>
  <study_first_submitted_qc>October 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2009</study_first_posted>
  <last_update_submitted>June 10, 2019</last_update_submitted>
  <last_update_submitted_qc>June 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostaglandins</keyword>
  <keyword>vascular injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Vascular System Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

